Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2019-08-13 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a formal communication addressed to stock exchanges (NSE and BSE) reporting the outcome of a Board of Directors meeting held on 13th August 2019. It includes approval of standalone and consolidated unaudited financial results for the quarter ended 30th June 2019, along with a limited review report by auditors. Additionally, it announces appointments of new directors. The document contains actual financial data for the quarter and is not merely an announcement of a report or a certification. The presence of unaudited quarterly financial results and auditor's limited review indicates this is an Interim / Quarterly Report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2019-08-13 English
Morepen Laboratories Ltd has informed BSE regarding Loss of Share Certificates of the Company.
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) informing them about the loss of share certificates and the request for issuance of duplicate share certificates. It references Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to share certificate loss and related disclosures. The content is a notification about a specific event related to share certificates, not a financial report, earnings release, or management discussion. It is not a report publication announcement or a certification. The document is best classified as a Regulatory Filing (RNS) because it is a regulatory disclosure that does not fit into other specific categories like share issue or director dealings.
2019-08-09 English
Board Meeting — Financial Results
Regulatory Filings
2019-08-06 English
MOREPEN LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2019 ,inter alia, to consider and approve the Un-audited Financial ....
Board/Management Information Classification · 95% confidence The document is a notice of a Board Meeting scheduled to consider and approve unaudited financial results for the quarter ended June 30, 2019. It is addressed to stock exchanges and references compliance with SEBI regulations. The document does not contain the financial results themselves but is an announcement of the meeting where such results will be considered. The document length is short (1969 characters) and it serves as an intimation rather than a report. Therefore, it fits the category of Board/Management Information (MANG), which includes announcements of board meetings and related management information.
2019-08-06 English
Morepen Laboratories Ltd has informed BSE regarding Loss of Share Certificates of the Company.
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) regarding the loss of share certificates and the request for issuance of duplicate share certificates. It references Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to reporting loss of share certificates. The content is an official notification about a shareholder's lost share certificates and does not contain financial data, earnings, management discussion, or any report publication. It is not a report or announcement of financial results, nor a regulatory filing about corporate governance or capital changes. The document is a regulatory announcement related to share certificate loss, which fits best under Regulatory Filings (RNS) as it is a compliance-related notification to stock exchanges without financial statements or report content.
2019-07-26 English
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding judgement passed by National Company Law Appellate Tribunal ('NCLAT'), ....
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, addressed to stock exchanges. It discusses a judgment by the National Company Law Appellate Tribunal (NCLAT) upholding a previous order by the National Company Law Tribunal (NCLT) regarding cancellation of shares allotted to fixed deposit holders and the company's obligations following the court order. The document is a notification of a legal and regulatory development affecting the company, not a financial report or detailed management discussion. It is relatively short (4216 characters) and serves as an official regulatory announcement to stock exchanges. It does not contain financial statements, earnings data, or detailed management analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance disclosures that do not fit other specific categories.
2019-07-24 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.